文献速递青光眼神经眼科

局部Rho激酶抑制对实验性小鼠青光眼和视神经病变的神经保护机制

The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

在340只小鼠中局部单眼间断给予2%利帕舒地尔(Rip)或平衡盐溶液(BSS),通过微珠前房注射诱导青光眼或视神经夹伤,评估视网膜神经节细胞(RGC)丢失和轴突计数。6周青光眼时Rip组RGC轴突丢失6.6±13.3% vs BSS组36.3±30.9%(P=0.04),夹伤后Rip组RGC胞体丢失68.6±8.2% vs BSS组80.5±5.7%(P=0.006)。结论认为局部Rip减少RGC丢失,机制涉及抑制视网膜和视神经的ROCK信号及对RGC和星形胶质细胞反应的影响。

要点

  • 6周青光眼模型中,Rip组RGC轴突丢失6.6±13.3%,BSS组36.3±30.9%(P=0.04)。
  • 视神经夹伤后Rip组RGC胞体丢失68.6±8.2%,低于BSS组的80.5±5.7%(P=0.006)。
  • 局部Rip减少青光眼和视神经夹伤中的RGC丢失,并抑制视网膜和视神经的ROCK信号。

核心结论

  • 局部Rip减少青光眼和视神经夹伤中的RGC丢失,并抑制视网膜和视神经的ROCK信号。
  • 神经保护机制似乎涉及对RGC和星形胶质细胞对眼压升高反应的影响。

研究设计与样本

  • 在340只小鼠中,计划性局部单眼间断给予2% Rip或BSS盐水滴眼。
  • 前房微珠注射诱导青光眼使眼压从1天升高至6周,其他小鼠接受视神经夹伤。
  • 使用视网膜全铺片抗RBPMS标记和视神经轴突计数评估RGC丢失,用β-淀粉样前体蛋白(APP)免疫定位定量轴突运输,用Micro-Western(Wes)分析定量蛋白表达。
  • 评估ROCK通路分子免疫荧光表达、星形胶质细胞结构定量变化和离体眼球视神经生物力学应变,并在不同视神经区域进行ROCK活性测定。

主要发现

  • 6周青光眼时,Rip组平均RGC轴突丢失6.6±13.3%,BSS组36.3±30.9%(P=0.04,每组n=10)。
  • 视神经夹伤后RGC胞体丢失Rip组68.6±8.2%,低于BSS组80.5±5.7%(P=0.006,每组n=10)。
  • 6周青光眼后RGC胞体丢失Rip组34±5.0%,低于BSS组51±8.1%(P=0.03,每组n=10)。
  • 无髓鞘视神经(UON)内APP轴突运输未受Rip影响,Rip和BSS处理小鼠的最大主机械应变增加相似。
  • 青光眼眼中Rip降低视网膜ROCK 1和2活性;BSS青光眼眼视网膜中pROCK2/ROCK2蛋白比值升高,而Rip青光眼眼未升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to delineate the neuroprotective mechanisms of topical 2% ripasudil (Rip), a Rho kinase (ROCK) inhibitor. METHODS: In 340 mice, scheduled 2% Rip or balanced salt solution (BSS) saline drops were intermittently, unilaterally delivered. Intracameral microbead glaucoma (GL) injection increased intraocular pressure (IOP) from 1 day to 6 weeks (6W), whereas other mice underwent optic nerve (ON) crush. Retinal ganglion cell (RGC) loss was assessed using retinal wholemount anti-RNA Binding Protein with Multiple Splicing (RBPMS) labeling and ON axon counts. Axonal transport was quantified with β-amyloid precursor protein (APP) immunolocalization. Micro-Western (Wes) analysis quantified protein expression. Immunofluorescent expression of ROCK pathway molecules, quantitative astrocyte structural changes, and ON biomechanical strains (explanted eyes) were evaluated. ROCK activity assays were conducted in separate ON regions. RESULTS: At 6W GL, mean RGC axon loss was 6.6 ± 13.3% in Rip and 36.3 ± 30.9% in BSS (P = 0.04, n = 10/group). RGC soma loss after crush was lower with Rip (68.6 ± 8.2%) than BSS (80.5 ± 5.7%, P = 0.006, n = 10/group). After 6W GL, RGC soma loss was lower with Rip (34 ± 5.0%) than BSS (51 ± 8.1%, P = 0.03, n = 10/group). Axonal transport of APP within the unmyelinated ON (UON) was unaffected by Rip. Maximum principal mechanical strains increased similarly in Rip and BSS-treated mice. Retinal ROCK 1 and 2 activity was reduced by Rip in GL eyes. The pROCK2/ROCK2 protein ratio rose in the retina of BSS GL eyes, but not in Rip GL eyes. CONCLUSIONS: Topical Rip reduced RGC loss in GL and ON crush, with suppression of ROCK signaling in the retina and ON. The neuroprotection mechanisms appear to involve effects on both RGC and astrocyte responses to IOP elevation.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Quillen SE, Kimball EC, Ritter-Gordy KA, et al. The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy. Invest Ophthalmol Vis Sci. 2024. PMID: 39565302. doi:10.1167/iovs.65.13.43

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。